loan

subject: Aarkstore Enterprise-womens Health Diagnostic Testing [print this page]

Table of Contents :
Table of Contents :

1.0 Overview 7

1.1 Statement of Report 7

1.2 Scope of this Report 7

1.3 Methodology 8

1.4 Executive Summary 9

2.0 Introduction - Sector Overview 11

2.1 Global Diagnostic Products Industry 11

3.0 Womens Health Testing Market Analysis in Size, Growth and Share 13

3.1 Global Womens Health Testing Markets 13

3.1.1 Market Drivers in the Womens Health Diagnostics Testing Sector 13

3.1.1.1 Market Segments for Womens Health Testing 13

3.1.1.2 Key Players in the Womens Health Diagnostics Testing Segment 14

3.1.1.3 Womens Health Testing Sector Analysis 15

3.2 U.S. Womens Health Testing Market 15

3.2.1 Market Overview 15

3.2.2 Diagnostic Test Categories 16

3.3 European Womens Health Diagnostic Test Market 17

3.3.1 German Womens Care Diagnostic Market 19

3.3.2 U.K. Womens Care Testing Diagnostic Market 22

3.3.2.1 U.K. Market Statistics 22

3.3.2.2 U.K. Competitive Analysis 23

3.3.2.3 U.K. Market Access 24

3.3.3 French Womens Care Diagnostic Market 25

3.3.4 Italian Womens Care Diagnostic Market 25

3.3.5 Spanish Womens Care Diagnostic Market 26

3.4 Japanese Womens Care Testing Market 26

3.5 Chinese Womens Care Market 27

3.6 Rest of the World Womens Care Testing Market 28

4.0 Womens Health Testing Individual Markets 30

4.1 Pregnancy Testing 30

4.2 Osteoporosis Testing 36

4.2.1 In Vitro Blood Tests 40

4.2.2 Bone Densitometry Devices 42

4.3 Prenatal Screening Testing 44

4.3.1 Cystic Fibrosis 44

4.3.2 Prenatal Genetic Testing 47

4.3.3 Fragile X Syndrome 49

4.3.4 Tay-Sachs Disease 49

4.4 Fertility Testing 49

4.5 Breast Cancer 52

4.5.1 CA 15-3 54

4.5.2 CA 27-29 54

4.5.3 BRCA1 Breast and Ovarian Cancer Gene 54

4.5.4 BRCA2 Breast Cancer Gene 54

4.5.5 Tissue polypeptide antigen (TPA) 56

4.5.6 DNA Ploidy and S-phase Fraction 56

4.5.7 Estrogen and Progesterone Receptor (ER and PR) 56

4.5.8 HER-2 56

4.5.9 HER-2 and Herceptin 57

4.5.10 p53 57

4.5.11 NMP66 57

4.5.12 Mammastatin 57

4.6 Ovarian Cancer 58

4.6.1 CA 125 II 58

4.6.2 Steroid Hormone Receptors 60

4.6.3 Epidermal Growth Factor Receptor (EGFR) 60

4.6.4 HER-2/neu 60

4.6.5 P53 Tumor Suppressor Gene 60

4.6.6 Lysophospholipids 60

4.7 Cervical Cancer 61

4.7.1 Pap Smears 62

4.7.2 Human Papillomavirus (HPV) Testing 65

4.8 Miscellaneous Testing 69

4.8.1 Estriol 69

4.8.2 Fetal Fibronectin (fFN) 70

4.8.3 Vaginal pH and Vaginitis 70

4.9 Human Immunodeficiency Virus (HIV) 71

4.10 Infectious Disease Testing 72

4.10.1 Strep Testing 72

4.10.2 Chlamydia 75

4.10.3 Methicillin-Resistant Staphylococcus Aurea (MRSA) 76

4.10.4 Hepatitis 77

For more information please contact :

http://www.aarkstore.com/reports/Womens-Health-Diagnostic-Testing-1340.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise

Contact: Neel

Email: press@aarkstore.com

http://www.aarkstore.com

by: Aarkstore Enterprise

welcome to loan (http://www.yloan.com/)